Sign in Subscribe
Pharmaceutical industry

DiObex, Inc. Begins Treating Patients with Type 2 Diabetes in Randomized Clinical Trial

Strategic Insights

— 2 min read

DiObex, Inc. has announced the initiation of a clinical trial to evaluate the safety and pharmacokinetics of DIO-902, a cortisol synthesis inhibitor, in patients with type 2 diabetes. The 2-week trial will assess the effects of three different dose levels of DIO-902 on glucose levels, blood pressure, and cholesterol. According to the company, preclinical studies have shown that DIO-902 is a more effective and safer alternative to the racemate of ketoconazole, which has been used to treat type 2 diabetes. The development of a drug that can manage multiple risk factors simultaneously would be a significant breakthrough in the treatment of type 2 diabetes, with significant implications for patient care and outcomes.

Key Takeaways:

  • DiObex, Inc. has initiated a randomized, placebo-controlled clinical trial to evaluate the safety and pharmacokinetics of DIO-902, a cortisol synthesis inhibitor, in patients with type 2 diabetes.
  • The 2-week trial will assess the effects of three different dose levels of DIO-902 on glucose levels, blood pressure, and cholesterol.
  • Preclinical studies have shown that DIO-902 is a more effective and safer alternative to the racemate of ketoconazole, which has been used to treat type 2 diabetes.
  • The development of a drug that can manage multiple risk factors simultaneously would be a significant breakthrough in the treatment of type 2 diabetes, with significant implications for patient care and outcomes.
  • Daniel Green, President of DiObex, commented on the company's excitement about the clinical development of DIO-902, citing the target's popularity among big pharma companies.
  • DIO-902 has been shown to be responsible for virtually all of the cortisol synthesis inhibitory activity present in the racemate of ketoconazole.
  • Dr. Timothy Stewart, Vice President of Research at DiObex, highlighted the substantial clinical benefits of inhibiting cortisol synthesis, including improved glucose control and lowered blood pressure and cholesterol.
  • Dr. Bernice Welles, Vice President of Development at DiObex, noted that a drug that can manage multiple risk factors simultaneously would be a significant advance in the treatment of type 2 diabetes.

Statistics:

  • The clinical trial will involve 2 weeks of treatment with DIO-902.
  • Preclinical studies have shown that DIO-902 is more effective and safer than the racemate of ketoconazole.
  • 3 dose levels of DIO-902 will be assessed in the clinical trial.

Sources:

  • DiObex, Inc.
  • Daniel Green, President of DiObex
  • Dr. Timothy Stewart, Vice President of Research at DiObex
  • Dr. Bernice Welles, Vice President of Development at DiObex
  • Health & Medicine Week editors
  • NewsRx.com
  • Copyright 2006, Health & Medicine Week via NewsRx.com.

Read more